The effects of a 12-to 24-month treatment with depot long-acting octreotide (OCT-LAR) on
hormone profile, tumor mass, and clinical symptoms were reported in 36 patients with active …

Context: Short and long-acting somatostatin (SRIF) analogs are approved for clinical use in
acromegaly. Recent analysis of the relative efficacy of octreotide LAR and lanreotide SR on …

Previously, we have shown somatostatin receptor (SSTR) subtype-specific regulation of
growth hormone (GH), thyroid-stimulating hormone, and prolactin (PRL) secretion in human …

The treatment of acromegaly and hyperprolactinaemia has been improved by the availability
of effective and welltolerated slow-release somatostatin analogues and dopamine agonists …

Traditionally, suppression of GH measured by polyclonal RIA to less than 2.0 μg/L after oral
glucose was accepted as evidence of remission after transsphenoidal surgery for …

Since the original description by Pierre Marie over a century ago, acromegaly has been
known to be associated with an increased morbidity and mortality. Early epidemiological …

abstract Acromegaly, an indolent disorder of growth hormone (GH) hypersecretion is most
typically caused by a somatotroph cell adenoma and may be treated by several modalities …

Indium-111 is a gamma rays emitting isotope with a relatively long half-live of 2.8 days.
Pentetreotide (DTPA-Octreotide) is a somatostatin analog mainly binding to SSTR2 carrying …

The effects of octreotide (up to 5 yr) as primary treatment in 26 patients with acromegaly
were compared with those in 81 patients with acromegaly who received octreotide as …

OBJECTIVE: Transsphenoidal surgery is the preferred treatment modality for growth
hormone (GH)-secreting pituitary adenomas. In many series, the reported postoperative …